Head to Head Review: Kymera Therapeutics (NASDAQ:KYMR) & Gene Biotherapeutics (OTCMKTS:CRXM)

Kymera Therapeutics (NASDAQ:KYMR) and Gene Biotherapeutics (OTCMKTS:CRXM) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, analyst recommendations and institutional ownership.

Profitability

This table compares Kymera Therapeutics and Gene Biotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-191.26%	-24.96%	-20.27%
Gene Biotherapeutics	N/A	N/A	N/A

Earnings & Valuation

This table compares Kymera Therapeutics and Gene Biotherapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$87.56 million	27.60	-$146.96 million	($2.34)	-15.95
Gene Biotherapeutics	N/A	N/A	N/A	N/A	N/A

Gene Biotherapeutics has lower revenue, but higher earnings than Kymera Therapeutics.

Analyst Ratings

This is a summary of recent recommendations for Kymera Therapeutics and Gene Biotherapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	0	3	13	1	2.88
Gene Biotherapeutics	0	0	0	0	0.00

Kymera Therapeutics presently has a consensus price target of $55.06, suggesting a potential upside of 47.54%. Given Kymera Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Kymera Therapeutics is more favorable than Gene Biotherapeutics.

Summary

Kymera Therapeutics beats Gene Biotherapeutics on 5 of the 8 factors compared between the two stocks.

About Kymera Therapeutics

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

About Gene Biotherapeutics

Gene Biotherapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of angiogenic gene therapy biotherapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product candidate is Generx, an angiogenic gene therapy product candidate in Phase 3 clinical trials for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. It is also developing Generx for ischemia-related cardiovascular and cerebral therapeutic indications. Gene Biotherapeutics, Inc. has an agreement with Fujifilm Diosynth Biotechnologies for the manufacture of Generx angiogenic gene therapy product for Phase 3 clinical evaluation. The company was formerly known as Taxus Cardium Pharmaceuticals Group, Inc. and changed its name to Gene Biotherapeutics, Inc. in January 2018. Gene Biotherapeutics, Inc. was incorporated in 2003 and is headquartered in San Diego, California.